Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001209191-23-040338

Options or other derivatives

  • President and CFO acquired 19,787,969 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Alspaugh Jonathan President and CFO 2023-06-22 Grant or award · Employee Stock Option (right to buy) +19,787,969 19,787,969 D: show line 1 in the form
Loading xslF345X04/doc4.xml…